| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
AT177 IND submission and Phase 1a initiation on track for the first half of 2027 |
| 09 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On November 3, 2026, each of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appointed to the Board of Directors (the “Board”) of Azora Therapeutics, Inc. (formerly known as Adial Pharmaceuticals, Inc.) (the “Company”). Dr. H... |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis |
| 16 Oct 2026 |
8-K: Other Events
As previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 18, 2026, on September 17, 2026, the Company convened it... |
| 02 Oct 2026 |
8-K: Other Events
As previously disclosed in that Current Report on Form 8-K filed by Adial Pharmaceuticals, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”) on September 18, 2026, on September 17, 2026, the Company convened it... |
| 18 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to Prior Plan. The Plan is the successor to the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; and (ii) all outstanding awards granted under the Prior Plan will remain su... |
| 16 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
The following unaudited pro forma condensed financial information presents the historical unaudited consolidated balance sheet as of June 30, 2026 of Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), adjusted to give effect to (i) ... |
| 25 Aug 2026 |
8-K: Unregistered Sales of Equity Securities
On August 19, 2026, Adial Pharmaceuticals, Inc. (the “Company”) granted an option to purchase 307,814 shares of Company common stock to an individual as a material inducement to such person becoming an employee of the Company. The option... |
| 21 Aug 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On August 18, 2026, Adial Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the stockholders’ equity reported in the Company’s Quarterly Re... |
| 17 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative colitis, to its pipeline |
| 13 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
As of August 10, 2026, Adial Pharmaceuticals, Inc. (the “Company”) anticipates that the employment of its current President and Chief Executive Officer, Cary Claiborne, will be terminated effective promptly after the Company’s 2026 Annua... |
| 11 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is entered into as of June 11, 2026, by and among ADIAL PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), ADIAL MERGER SUB I, INC., a Delaware corporation and wholly owned subs... |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition
Glen Allen, VA – May 11, 2026 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related d... |
| 09 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Restricted Stock Award Agreement (this “Agreement”), dated as of the “Award Date” set forth in the attached Exhibit A, is entered into between Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the individual i... |
| 06 Mar 2026 |
8-K: Results of Operations and Financial Condition
Glen Allen, VA – March 6, 2026 – Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related ... |
| 03 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement |
| 24 Feb 2026 |
8-K: Other Events
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 |
| 04 Feb 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 |
| 06 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 5, 2025, James W. Newman, Jr., a member of the Board of Directors (the “Board”) of Adial Pharmaceuticals, Inc. (the “Company”), notified the Company of his decision to resign, effective immediately, from his position as a memb... |
| 01 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN... |
Loading...